Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 155 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Fountzilas, George  [Clear All Filters]
2013
Kotoula, V., Kalogeras K. T., Kouvatseas G., Televantou D., Kronenwett R., Wirtz R. M., et al. (2013).  Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research.. Virchows Arch. 462(2), 141-54.
2012
Stevens, K. N., Fredericksen Z., Vachon C. M., Wang X., Margolin S., Lindblom A., et al. (2012).  19p13.1 is a triple-negative-specific breast cancer susceptibility locus.. Cancer Res. 72(7), 1795-803.
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Pectasides, D., Papaxoinis G., Kotoula V., Fountzilas H., Korantzis I., Koutras A., et al. (2012).  Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.. Oncol Rep. 27(1), 216-24.
Korantzis, I., Kalogeras K. T., Papaxoinis G., Kotoula V., Koutras A., Soupos N., et al. (2012).  Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.. Anticancer Res. 32(10), 4569-80.
Kotoula, V., Krikelis D., Karavasilis V., Koletsa T., Eleftheraki A. G., Televantou D., et al. (2012).  Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).. BMC Cancer. 12, 342.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., et al. (2012).  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.. Clin Breast Cancer. 12(3), 183-93.
Murray, S., Karavasilis V., Bobos M., Razis E., Papadopoulos S., Christodoulou C., et al. (2012).  Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.. J Exp Clin Cancer Res. 31, 77.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.
Panagopoulou, P., Gogas H., Dessypris N., Maniadakis N., Fountzilas G., & Petridou E. Th (2012).  Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study.. Eur J Epidemiol. 27(11), 857-66.
Fountzilas, G., Christodoulou C., Bobos M., Kotoula V., Eleftheraki A. G., Xanthakis I., et al. (2012).  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.. J Transl Med. 10, 212.
Kosmidis, P. A., Syrigos K., Kalofonos H. P., Dimopoulos M-A., Skarlos D., Pavlidis N., et al. (2012).  Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.. Anticancer Res. 32(1), 175-81.
Iliadis, G., Kotoula V., Chatzisotiriou A., Televantou D., Eleftheraki A. G., Lambaki S., et al. (2012).  Volumetric and MGMT parameters in glioblastoma patients: survival analysis.. BMC Cancer. 12, 3.
Pectasides, D., Papaxoinis G., Kalogeras K. T., Eleftheraki A. G., Xanthakis I., Makatsoris T., et al. (2012).  XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.. BMC Cancer. 12, 271.
2011
Stevens, K. N., Vachon C. M., Lee A. M., Slager S., Lesnick T., Olswold C., et al. (2011).  Common breast cancer susceptibility loci are associated with triple-negative breast cancer.. Cancer Res. 71(19), 6240-9.
Haiman, C. A., Chen G. K., Vachon C. M., Canzian F., Dunning A., Millikan R. C., et al. (2011).  A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.. Nat Genet. 43(12), 1210-4.
Pectasides, E., Rampias T., Kountourakis P., Sasaki C., Kowalski D., Fountzilas G., et al. (2011).  Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma.. Clin Cancer Res. 17(9), 2947-54.
Tselis, N., Ratka M., Vogt H-G., Kolotas C., Baghi M., Baltas D., et al. (2011).  Hypofractionated accelerated CT-guided interstitial ¹⁹²Ir-HDR-Brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer.. Radiother Oncol. 98(1), 57-62.
Fountzilas, G., Kourea H. P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., et al. (2011).  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.. Anticancer Res. 31(9), 3007-18.
Pentheroudakis, G., Batistatou A., Kalogeras K. T., Kronenwett R., Wirtz R. M., Bournakis E., et al. (2011).  Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.. Breast Cancer Res Treat. 127(1), 179-93.
Papadimitriou, C. A., Papakostas P., Karina M., Malettou L., Dimopoulos M. A., Pentheroudakis G., et al. (2011).  A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.. BMC Med. 9, 10.
Kotoula, V., Lambaki S., Televantou D., Kalogera-Fountzila A., Nikolaou A., Markou K., et al. (2011).  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.. Transl Oncol. 4(1), 47-58.
2010
Koutras, A. K., Fountzilas G., Makatsoris T., Peroukides S., & Kalofonos H. P. (2010).  Bevacizumab in the treatment of breast cancer.. Cancer Treat Rev. 36(1), 75-82.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές